T CELL-ANTIGEN COUPLER WITH VARIOUS CONSTRUCT OPTIMIZATIONS

• US 20200024345A1
• Filed: 06/14/2019
• Published: 01/23/2020
• Est. Priority Date: 07/17/2018
• Status: Active Grant

• Current Assignee: Mcmaster University
• Original Assignee: Mcmaster University
• Inventors: BRAMSON, Jonathan Lorne, HELSEN, Christopher W., HAMMILL, Joanne Alicia, MWAWASI, Kenneth Anthony
• Granted Patent: US 10,640,562 B2
• Time in Patent Office: Days
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: C07K 14/70514 CD4
• CPC Class Codes: C07K 16/2803 against the immunoglobulin superfamily
• CPC Class Codes: C07K 16/2809 against the T-cell receptor (TcR)-CD3 complex
• CPC Class Codes: C07K 16/2878 against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
• CPC Class Codes: C07K 16/32 against translation products of oncogenes
• CPC Class Codes: C07K 2317/24 containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
• CPC Class Codes: C07K 2317/31 multispecific
• CPC Class Codes: C07K 2317/522 CH1 domain
• CPC Class Codes: C07K 2317/622 Single chain antibody (scFv)
• CPC Class Codes: C07K 2317/73 Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
• CPC Class Codes: C07K 2318/20 Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
• CPC Class Codes: C07K 2319/03 containing a transmembrane segment
• CPC Class Codes: C07K 2319/33 fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Abstract

A trifunctional molecule is provided, comprising (i) a target-specific ligand, (ii) a ligand that binds a protein associated with a TCR complex, and (iii) a T cell receptor signaling domain polypeptide. Variants of the molecule are provided, including variants that exhibit optimized surface expression, transduction efficiency, and effector functionality. Variations include, for example, different ligands that bind CD3 epsilon (e.g., OKT3, L2K, F6A, UCHT1 and humanized UCHT1), different signaling domains, and different linkers between domains.

Claims

1-99. -99. (canceled)

100. A nucleic acid sequence encoding a CD19 Trifunctional T cell-antigen coupler (CD19-TAC) comprising:

(a) a first polynucleotide encoding a ligand that selectively binds a CD19 antigen;

(b) a second polynucleotide encoding a humanized variant of a UCHT1 (huUCHT1) ligand comprising a Y177T mutation (huUCHT1 (Y177T)) that binds CD3; and

(c) a third polynucleotide encoding a polypeptide comprising a CD4 cytosolic domain and a CD4 transmembrane domain;

wherein ligand encoded by (a), ligand encoded by (b), and polypeptide encoded by (c) are fused directly to each other, or joined by at least one linker.

101. The nucleic acid sequence of claim 100, wherein the nucleic acid sequence does not encode a co-stimulatory domain, an activation domain, or both a co-stimulatory domain and an activation domain.

102. The nucleic acid sequence of claim 100, wherein the ligand that selectively binds the CD19 antigen is a single chain variable fragment (scFv).

103. The nucleic acid sequence of claim 100, wherein the ligand that selectively binds the CD19 antigen comprises an amino acid sequence having at least 80%, at least 90%, or at least 95% sequence identity with SEQ ID NO:

36.

104. The nucleic acid sequence of claim 100, wherein the ligand that selectively binds the CD19 antigen comprises an amino acid sequence of SEQ ID NO:

36.

105. The nucleic acid sequence of claim 100, wherein the huUCHT1 (Y177T) ligand is a single chain antibody.

106. The nucleic acid sequence of claim 100, wherein the huUCHT1 (Y177T) ligand comprises an amino acid sequence having at least 80%, at least 90%, or at least 95% sequence identity with SEQ ID NO:

46.

107. The nucleic acid sequence of claim 100, wherein the huUCHT1 (Y177T) ligand comprises an amino acid sequence of SEQ ID NO:

46.

108. The nucleic acid sequence of claim 100, wherein the third polynucleotide encodes a polypeptide comprising an amino acid sequence having at least 80%, at least 90%, or at least 95% sequence identity with SEQ ID NO:

18.

109. The nucleic acid sequence of claim 100, wherein the third polynucleotide encodes a polypeptide comprising an amino acid sequence of SEQ ID NO:

18.

110. The nucleic acid sequence of claim 100, wherein the at least one linker is a G45 flexible linker, a large protein domain, a long helix structure, or a short helix structure.

111. The nucleic acid sequence of claim 100, wherein the at least one linker comprises an amino acid sequence having at least 80%, at least 90%, or at least 95% sequence identity with SEQ ID NO:

12, SEQ ID NO;

32, SEQ ID NO;

30, or SEQ ID NO;

28.

112. The nucleic acid sequence of claim 100, wherein the at least one linker comprises an amino acid sequence of SEQ ID NO:

12, SEQ ID NO;

32, SEQ ID NO;

30, or SEQ ID NO;

28.

113. The nucleic acid sequence of claim 100, wherein the CD3 is expressed on a cell expressing the second polynucleotide.

114. The nucleic acid sequence of claim 100, wherein the CD19-TAC comprises a nucleic acid sequence having at least 80%, at least 90%, or at least 95% sequence identity with SEQ ID NO:

63.

115. The nucleic acid sequence of claim 100, wherein the CD19-TAC comprises an amino acid sequence having at least 80%, at least 90%, or at least 95% sequence identity with SEQ ID NO:

64.

116. The nucleic acid sequence of claim 100, wherein the CD19-TAC comprises a sequence of SEQ ID NO:

63 or SEQ ID NO;

64.

117. A vector construct comprising:

(a) a nucleic acid sequence of claim 100; and

(b) a promoter functional in a mammalian cell.

118. A composition comprising the vector of claim 117, and an excipient.

119. A polypeptide encoded by the nucleic acid sequence of claim 100.